Invesco Ltd. grew its holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 1,956.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 214,490 shares of the company's stock after acquiring an additional 204,061 shares during the period. Invesco Ltd. owned about 0.35% of Pulse Biosciences worth $3,734,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Barclays PLC increased its position in shares of Pulse Biosciences by 361.4% in the 3rd quarter. Barclays PLC now owns 30,306 shares of the company's stock valued at $530,000 after purchasing an additional 23,738 shares during the last quarter. Geode Capital Management LLC boosted its stake in Pulse Biosciences by 7.8% in the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company's stock valued at $8,020,000 after acquiring an additional 33,200 shares in the last quarter. Franklin Resources Inc. purchased a new position in Pulse Biosciences during the 3rd quarter worth approximately $378,000. SG Americas Securities LLC acquired a new position in shares of Pulse Biosciences in the 4th quarter valued at $193,000. Finally, Oppenheimer & Co. Inc. acquired a new position in Pulse Biosciences in the fourth quarter valued at $311,000. 76.95% of the stock is owned by institutional investors and hedge funds.
Pulse Biosciences Stock Performance
Pulse Biosciences stock opened at $17.91 on Monday. Pulse Biosciences, Inc. has a 1-year low of $6.66 and a 1-year high of $25.00. The stock's 50 day moving average price is $17.00 and its 200 day moving average price is $18.02.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research note on Monday, March 31st.
Read Our Latest Stock Report on PLSE
Pulse Biosciences Company Profile
(
Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
